Maduck Sean 4

What Happened
Sean Maduck, President, Corcept Endocrinology at Corcept Therapeutics (CORT), was granted 140,000 derivative shares on February 27, 2026. The award was reported at $0.00 (no cash paid) and is a grant/award-type transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-27; Transaction type: Grant / Award (derivative); Amount: 140,000 shares; Reported price: $0.00.
• Vesting: Footnote indicates vesting "ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period," subject to continued service.
• Shares owned after transaction: Not stated in this Form 4.
• Filing timeliness: Form filed 2026-03-03 — within the required two-business-day window following the Feb 27 transaction.
• Other: The form notes a power of attorney on file with the SEC.

Context
This is a compensation-related derivative grant (commonly restricted stock units or similar) that vests monthly over four years and does not involve an immediate cash purchase or sale. Such awards are typical executive compensation and do not by themselves indicate an immediate market action (no immediate sale noted).